Quote | Gain Therapeutics Inc. (NASDAQ:GANX)
Last: | $2.63 |
---|---|
Change Percent: | 0.37% |
Open: | $2.68 |
Close: | $2.63 |
High: | $2.8 |
Low: | $2.5301 |
Volume: | 59,244 |
Last Trade Date Time: | 05/17/2024 03:00:00 am |
News | Gain Therapeutics Inc. (NASDAQ:GANX)
2024-05-14 13:54:40 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Gain Therapeutics (NASDAQ: GANX ) just reported results for the first quarter of 2024. Gain Therapeutics reported earnings per share of -22 cents. This was above the analy...
2024-05-14 09:12:37 ET More on Gain Therapeutics Seeking Alpha’s Quant Rating on Gain Therapeutics Historical earnings data for Gain Therapeutics Financial information for Gain Therapeutics Read the full article on Seeking Alpha For further det...
Message Board Posts | Gain Therapeutics Inc. (NASDAQ:GANX)
Subject | By | Source | When |
---|---|---|---|
,,,,,,,REVERSAL OF FORTUNE!!! OUCH | THEMASTERS_SON | investorshub | 04/12/2022 7:22:34 PM |
Zoom presentation with Gain Therapeutics (Nasdaq: $GANX) this | RoadShowPartner | investorshub | 09/20/2021 9:18:07 PM |
Gain Therapeutics to Present at the Oppenheimer Fall | ProfitScout | investorshub | 09/17/2021 2:11:00 PM |
$GANX today announced that Eric Richman, Chief Executive | StockHighAlert- | investorshub | 09/17/2021 12:37:42 PM |
Nice green start here $GANX | StockHighAlert- | investorshub | 09/16/2021 1:59:43 PM |
News, Short Squeeze, Breakout and More Instantly...
Gain Therapeutics Inc. Company Name:
GANX Stock Symbol:
NASDAQ Market:
BETHESDA, Md., May 14, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reports ...
Jet.AI Inc. (JTAI) is expected to report for Q1 2024 Forian Inc. (FORA) is expected to report $-0.02 for Q1 2024 Square Enix Holdings Co. Ltd (SQNXF) is expected to report for Q4 2024 Qutoutiao Inc. (QTT) is expected to report for Q4 2023 Molecular Partners AG (MOLN) is expected t...